

TRANSLATIONAL TARGET VALIDATION

The Path to Better Drugs?

Tuesday 20 June, 2017 | 09:00-17:00
Wellcome Genome Campus Conference Centre
Hinxton, Cambridgeshire, CB10 1RQ

DISCOVERY

FROM

CHARLES RIVER



DP

Discovery Pathway

Ch

Chemistry

B/D

Biology/Discovery Technologies

D/P S/I

DMPK/Pharmacology/Safety/In Vivo Models

Recognising that the increasing access to human genetic data and the rise of CRISPR/Cas9 has led to rapid changes in the field of target validation, we are bringing together researchers who share an interest in this important foundational step in the drug discovery process. Charles River is pleased to host this 1-day symposium, where we'll network with industry leaders, share best practices, review case studies, and discuss the future of translational target discovery.

We hope you enjoy this unique opportunity to interact with key scientists and learn about the latest advancements and technologies enabling translational target validation.

AGENDA

08:00-09:00	Registration and Breakfast
09:00-09:10	Welcome and Opening Remarks George McAllister, PhD Senior Director, Discovery - Charles River
SESSION 1	ADVANTAGES OF A TRANSLATIONAL APPROACH
09:10-09:45	Tagrisso (Osimertinib): The Journey of Discovery Jonathan Orme, BSc Associate Principal Scientist - Astra Zeneca
09:45-10:20	Optimization of Potent and Selective ATM Inhibitors Suitable for a Proof-of-Concept Study in HD Models Perla Breccia, PhD Team Leader, Medicinal Chemistry - Charles River
10:20-10:50	Networking Refreshment Break
10:50-11:25	Phenotypic Activity Driven Target Identification Professor Paul Wyatt, PhD, FRSE Head of Drug Discovery Unit, Director of the Wellcome Centre for Anti-Infectives Research - University of Dundee
11:25-11:45	Panel Discussion Moderator: George McAllister Panelists: Jonathan Orme, Perla Breccia, Paul Wyatt, Martin O'Rourke

KEYNOTE ADDRESS

11:45-12:30 **Fortune Favours the Prepared Mind - The XO1 Story**
Jim Huntington, PhD
Professor of Haemostasis - University of Cambridge

12:30-13:40 **Lunch**

SESSION 2 RECENT DEVELOPMENTS AND FUTURE DIRECTIONS

13:40-14:15 **RNAi and CRISPR/Cas9 Based *In Vivo* Models for Drug Discovery**
Prem K. Premrurut, MD, PhD
Founder, Chief Executive Officer - Mirimus

14:15-14:50 **"Click and Play" Protein Degradation and Chemical Biology in Cells**
Christopher N. Johnson, PhD
Senior Director of Medicinal Chemistry - Astex

14:50-15:20 **Networking Refreshment Break**

15:20-15:55 **Improving Target Identification and Prioritisation through Open Targets: an Integrated Programme of Experiments and Bioinformatics**
Ian Dunham, DPhil
Scientific Director - Open Targets

15:55-16:30 **Ventures into New Target Space: Drugging the DUB's**
Tim Harrison, PhD
Vice President, Drug Discovery - Almac Discovery

16:30-16:50 **Panel Discussion**
Moderator: George McAllister
Panelists: Jim Huntington, Prem K. Premrurut, Chris Johnson, Ian Dunham, Jamil Aarbiou

16:50-17:00 **Closing Remarks**
David Fischer, PhD
Executive Director, Biology DMPK - Charles River